Phibro Animal Health Corporation

PAHC Healthcare Drug Manufacturers Specialty & Generic

Phibro Animal Health Corporation’s revenue for fiscal 2026 (year ended June 2026) was $1.5 billion, up 17.1% from fiscal 2025. In the quarter to June 2026, revenue grew 4.77%, EPS grew 28.6%, free cash flow fell 35.7% and total debt rose 1.96%, each against the same quarter a year earlier. Dividend growth for ten consecutive years, revenue growth for five; insiders bought in the last twelve months.

38.82 0.84 +2.21%
Market cap
$1.5B
P/E
15.8×
Fwd P/E
11.1×
Dividend yield
1.24%
F-score
6/9
Altman Z
2.95
Beneish M
−2.39
Dividend safety
47/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

24.23 16.46 23.64 12.76
P/S ratio
1.17 1.03 1.50 0.84
P/FCF ratio
47.83 32.02 175.62 129.04
P/Operating CF
176.31 78.25 138.40 52.84
P/B ratio
5.26 4.56 6.20 3.30
EV/Sales
1.64 1.48 1.93 1.27
EV/EBITDA
11.74 9.79 12.46 7.75
EV/FCF
67.01 45.91 227.15 195.01
Current Ratio
3.09 3.05 3.17 2.96
Net Debt/EBITDA
10.17 10.30 11.41 10.48
Debt/Equity
2.38 2.20 2.03 1.90
Earnings Yield
4.13% 6.08% 4.23% 7.83%
Free Cash Flow Yield
2.09% 3.12% 0.57% 0.77%
Free Cash Flow per Share
(0.11) 0.20 0.02 0.13
Book value per Share
7.69 8.20 8.92 9.51
Free Cash Flow
(4.50) 8.26 0.89 5.23
EV/EBIT
15.95 12.86 16.12 9.90
Other line items

Show all line items

Columns are period end dates